Highlights from ESMO 2019

Optimal timing of radiotherapy following radical prostatectomy

Using PARP inhibitors to improve quality of life for patients with metastatic breast cancer

Holistic management of patients with ALK-positive NSCLC

Health-related quality of life for patients with metastatic pancreatic cancer: Updates from ESMO 2019

Key developments in pancreatic cancer from ESMO 2019

Melanoma highlights from ESMO 2019

BEACON: Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer

Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early triple-negative breast cancer

Improvement in OS with abemaciclib plus fulvestrant in pre-, peri- and postmenopausal HR-positive, HER2-negative advanced breast cancer resistant to hormonal therapy

Ovarian highlights from ESMO 2019

Comment: Nivolumab plus ipilimumab combination for advanced NSCLC